<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04818229</url>
  </required_header>
  <id_info>
    <org_study_id>CBP-307AU002</org_study_id>
    <nct_id>NCT04818229</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects</brief_title>
  <official_title>A Phase I, Single-center, Randomized, Double-blind, Double-dummy, Placebo- and Positive-Controlled Study to Investigate the Effects of CBP-307 on the QTc Interval in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Connect Biopharmaceuticals, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Connect Biopharmaceuticals, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effects of therapeutic and supratherapeutic oral doses of&#xD;
      CBP-307 on the QTc interval in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase I, randomized, double-blind, double-dummy, placebo-controlled,&#xD;
      positive-controlled, single-site study to investigate the effects of therapeutic and&#xD;
      supratherapeutic oral doses of CBP-307 on the QTc interval in healthy male and female&#xD;
      subjects. The study is divided into a treatment period of 21 days and a follow-up period of&#xD;
      10 ± 2 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change-from-baseline QT interval corrected for heart rate using Fridericia's method (QTcF)</measure>
    <time_frame>From Baseline to Day 16</time_frame>
    <description>Change from Baseline in QT interval corrected for heart rate using Fridericia's method (QTcF) to evaluate the effects of therapeutic and supratherapeutic CBP-307 plasma concentrations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change-from-baseline heart rate (HR)</measure>
    <time_frame>From Baseline to Day 16</time_frame>
    <description>Change from Baseline in heart rate (HR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change-from-baseline PR</measure>
    <time_frame>From Baseline to Day 16</time_frame>
    <description>Change from Baseline in PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change-from-baseline QRS</measure>
    <time_frame>From Baseline to Day 16</time_frame>
    <description>Change from Baseline in QRS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected change-from-baseline HR</measure>
    <time_frame>From Baseline to Day 16</time_frame>
    <description>Change from Baseline in HR with Placebo correction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected change-from-baseline QTcF</measure>
    <time_frame>From Baseline to Day 16</time_frame>
    <description>Change from Baseline in QTcF with Placebo correction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected change-from-baseline PR</measure>
    <time_frame>From Baseline to Day 16</time_frame>
    <description>Change from Baseline in PR with Placebo correction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected change-from-baseline QRS</measure>
    <time_frame>From Baseline to Day 16</time_frame>
    <description>Change from Baseline in QRS with Placebo correction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical outliers for QTcF</measure>
    <time_frame>From Baseline to Day 16</time_frame>
    <description>For categorical outliers, the number (percentage) of subjects as well as timepoints who had increases in absolute QTcF values &gt;450 and ≤480 msec, &gt;480 and ≤500 msec, or &gt;500 msec, and changes from predose baseline of &gt;30 and ≤60 msec, or &gt;60 msec.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical outliers for HR</measure>
    <time_frame>From Baseline to Day 16</time_frame>
    <description>For categorical outliers, decrease in HR from predose baseline &gt;25% to an HR &lt;50 bpm will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical outliers for PR</measure>
    <time_frame>From Baseline to Day 16</time_frame>
    <description>For categorical outliers, increase in PR from predose baseline &gt;25% to a PR &gt; 200 msec will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical outliers for QRS</measure>
    <time_frame>From Baseline to Day 16</time_frame>
    <description>For categorical outliers, increase in QRS from predose baseline &gt;25% to a QRS &gt;120 msec will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of treatment-emergent changes of T-wave morphology</measure>
    <time_frame>From Baseline to Day 16</time_frame>
    <description>For T-wave morphology, the analyses will be focused on change from baseline with counts (percentages) for both the number of subjects and the number of timepoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of treatment-emergent changes of U-wave presence</measure>
    <time_frame>From Baseline to Day 16</time_frame>
    <description>For U-wave presence, the analyses will be focused on change from baseline with counts (percentages) for both the number of subjects and the number of timepoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero extrapolated to infinity (AUCinf)</measure>
    <time_frame>From Baseline to Day 29 ± 2</time_frame>
    <description>Area under the concentration-time curve from time zero extrapolated to infinity (AUCinf) will be analyzed as a pharmacokinetic (PK) parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero to 24 hours postdose (AUC0-24)</measure>
    <time_frame>From Baseline to Day 29 ± 2</time_frame>
    <description>Area under the concentration-time curve from time zero to 24 hours postdose (AUC0-24) will be analyzed as a pharmacokinetic (PK) parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>From Baseline to Day 29 ± 2</time_frame>
    <description>Maximum observed concentration (Cmax) will be analyzed as a pharmacokinetic (PK) parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of the maximum observed concentration (tmax)</measure>
    <time_frame>From Baseline to Day 29 ± 2</time_frame>
    <description>Time of the maximum observed concentration (tmax) will be analyzed as a pharmacokinetic (PK) parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of Adverse Event (AE)</measure>
    <time_frame>From Baseline to Day 29 ± 2</time_frame>
    <description>All AEs will be listed and treatment-emergent AEs will be summarized using the descriptive methodology.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>Investigational Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapeutic and supratherapeutic multiple oral doses of CBP-307.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Moxifloxacin (positive control for method validation) and Placebo oral administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBP-307</intervention_name>
    <description>CBP-307 capsules oral administration.</description>
    <arm_group_label>Investigational Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-matched CBP-307</intervention_name>
    <description>Placebo-matched CBP-307 capsules oral administration.</description>
    <arm_group_label>Investigational Group 1</arm_group_label>
    <arm_group_label>Investigational Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin (Avelox)</intervention_name>
    <description>Moxifloxacin tablets oral administration。</description>
    <arm_group_label>Investigational Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-matched Moxifloxacin</intervention_name>
    <description>Placebo-matched Moxifloxacin tablets oral administration.</description>
    <arm_group_label>Investigational Group 1</arm_group_label>
    <arm_group_label>Investigational Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females, of any race, between 18 and 60 years of age, inclusive.&#xD;
&#xD;
          2. Body mass index between 18.0 and 30.0 kg/mE2, inclusive.&#xD;
&#xD;
          3. In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory&#xD;
             evaluations (congenital nonhemolytic hyperbilirubinemia [eg, suspicion of Gilbert's&#xD;
             syndrome based on total and direct bilirubin] is not acceptable) at screening and&#xD;
             confirmed at check-in as assessed by the investigator (or designee).&#xD;
&#xD;
          4. Females will not be pregnant or lactating, and females of childbearing potential and&#xD;
             males will agree to use contraception. Negative pregnancy test for females of&#xD;
             childbearing potential at screening (blood test) and check-in (urine test).&#xD;
&#xD;
          5. Supine diastolic blood pressure between 60 and 90 mmHg and systolic blood pressure&#xD;
             between 90 and 140 mmHg (inclusive) at screening on a single measurement (confirmed by&#xD;
             a single repeat, if necessary) following at least 5 minutes of rest.&#xD;
&#xD;
          6. No clinically significant history or presence of ECG findings as judged by the&#xD;
             investigator at screening and check-in, including each criterion as listed below:&#xD;
&#xD;
               1. Normal sinus rhythm (HR between 60 bpm and 100 bpm inclusive);&#xD;
&#xD;
               2. QTcF interval ≤450 msec for males and females;&#xD;
&#xD;
               3. QRS interval ≤110 msec; and confirmed by manual over-read if &gt;110 msec;&#xD;
&#xD;
               4. PR interval ≤200 msec.&#xD;
&#xD;
          7. Has serum potassium, calcium, and magnesium levels within the normal reference range&#xD;
             at screening, as judged by the investigator.&#xD;
&#xD;
          8. Able to swallow multiple tablets (based on subject's verbal confirmation).&#xD;
&#xD;
          9. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Subjects will be excluded from the study if they satisfy any of the following criteria at&#xD;
        the screening visit unless otherwise stated:&#xD;
&#xD;
          1. Subject is mentally or legally incapacitated or has had significant history of recent&#xD;
             mental health issues requiring medication and/or hospitalization at the time of the&#xD;
             screening visit or expected during the conduct of the study.&#xD;
&#xD;
          2. Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as&#xD;
             determined by the investigator (or designee). Note: Childhood asthma that is&#xD;
             considered recovered or seasonal allergies that are not currently active or requiring&#xD;
             treatment are allowed.&#xD;
&#xD;
          3. History of significant hypersensitivity, intolerance, or allergy to any drug compound,&#xD;
             food, or other substance, unless approved by the investigator (or designee).&#xD;
&#xD;
          4. History or presence of hypersensitivity or idiosyncratic reaction to the study drugs,&#xD;
             related compounds, or inactive ingredients.&#xD;
&#xD;
          5. History of significant multiple and/or severe allergies (eg, latex allergy, band-aids,&#xD;
             adhesive dressing, or medical tape), or has had an anaphylactic reaction or&#xD;
             significant intolerability to prescription or nonprescription drugs.&#xD;
&#xD;
          6. History of stomach or intestinal surgery or resection that would potentially alter&#xD;
             absorption and/or excretion of orally administered drugs within 6 months prior to the&#xD;
             first dose of study drug (uncomplicated appendectomy and hernia repair will be&#xD;
             allowed).&#xD;
&#xD;
          7. History or presence of:&#xD;
&#xD;
               1. Hypokalemia, in the opinion of the investigator (or designee);&#xD;
&#xD;
               2. Risk factors for Torsades de Pointes (eg, heart failure, cardiomyopathy, or&#xD;
                  family history of Long QT Syndrome);&#xD;
&#xD;
               3. Sick sinus syndrome, second, or third degree atrioventricular block, myocardial&#xD;
                  infarction, pulmonary congestion, cardiac arrhythmia, prolonged QT interval, or&#xD;
                  conduction abnormalities;&#xD;
&#xD;
               4. Repeated or frequent syncope or vasovagal episodes;&#xD;
&#xD;
               5. Hypertension, angina, bradycardia, or severe peripheral arterial circulatory&#xD;
                  disorders.&#xD;
&#xD;
          8. Clinically significant abnormalities (as judged by the investigator in laboratory&#xD;
             tests results [out-of-range results confirmed on repeat]), including but not limited&#xD;
             to the following parameters:&#xD;
&#xD;
               1. alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, or&#xD;
                  total bilirubin greater than 1.5 × upper limit of normal;&#xD;
&#xD;
               2. hemoglobin &lt;10 g/dL, WBC &lt;3.0 ×10E9/L, neutrophils &lt;1.5 ×10E9/L, lymphocytes &lt;0.8&#xD;
                  ×10E9/L and platelets &lt;100 ×10E9/L or &gt;1200 × 10E9/L;&#xD;
&#xD;
          9. History or evidence of alcoholism or drug/chemical abuse within 2 years prior to&#xD;
             check-in.&#xD;
&#xD;
         10. Alcohol consumption of &gt;10 units per week for males and females. One unit of alcohol&#xD;
             equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL)&#xD;
             of spirits.&#xD;
&#xD;
         11. Positive alcohol breath test result or positive urine drug screen (confirmed by&#xD;
             repeat) at screening or check-in.&#xD;
&#xD;
         12. Positive hepatitis panel, positive syphilis test, and/or positive human&#xD;
             immunodeficiency virus test.&#xD;
&#xD;
         13. Participation in a clinical study involving administration of an investigational drug&#xD;
             (new chemical entity) in the past 28 days prior to the first dose of study treatment&#xD;
             on Day 1. The 28-day window will be derived from the date of the last blood collection&#xD;
             or dosing, whichever is later, in the previous study to Day 1 of the current study.&#xD;
&#xD;
         14. Participation in a previous clinical study where subjects received CBP-307.&#xD;
&#xD;
         15. Administration of a Coronavirus Disease 2019 (COVID-19) vaccine in the past 28 days&#xD;
             prior to first dose of study treatment on Day 1.&#xD;
&#xD;
         16. Use or intend to use any prescription medications/products within 14 days prior to&#xD;
             first dose of study drug (Day 1) and throughout the study, unless deemed acceptable by&#xD;
             the investigator (or designee). Note: For females only, the use hormonal&#xD;
             contraception, hormone replacement therapy or oral, implantable, transdermal,&#xD;
             injectable, or intrauterine hormonal contraceptives within 14 days prior to Day 1 is&#xD;
             not acceptable, except for Mirena®.&#xD;
&#xD;
         17. Use or intend to use any drugs known to be significant inhibitors or inducers of CYP&#xD;
             enzymes and/or P-gp, including St. John's Wort, for days prior to the first dose of&#xD;
             study drug and throughout the study. Appropriate sources will be consulted by the&#xD;
             investigator or designee to confirm the lack of PK/PD interaction with the study drug.&#xD;
&#xD;
         18. Use or intend to use slow-release medications/products considered to still be active&#xD;
             within 14 days prior to check-in, unless deemed acceptable by the investigator (or&#xD;
             designee).&#xD;
&#xD;
         19. Use or intend to use any nonprescription medications/products including antacids,&#xD;
             vitamins (especially those containing magnesium, aluminum, iron, or zinc), minerals,&#xD;
             and phytotherapeutic/herbal/plant-derived preparations within 14 days prior to&#xD;
             check-in, unless deemed acceptable by the investigator (or designee).&#xD;
&#xD;
         20. Use of tobacco- or nicotine-containing products within 3 months prior to check-in, or&#xD;
             positive cotinine at screening or check-in.&#xD;
&#xD;
         21. Has been on a diet incompatible with the on-study diet (including an extreme diet&#xD;
             which resulted in a significant weight change for whatever reason), in the opinion of&#xD;
             the investigator, within the 28 days prior to the first dose of study treatment, and&#xD;
             throughout the study.&#xD;
&#xD;
         22. Consumption of caffeine/xanthine-containing foods or beverages within 48 hours prior&#xD;
             to check-in until discharge.&#xD;
&#xD;
         23. Ingestion of poppy seed-, Seville orange-, or grapefruit-containing foods or beverages&#xD;
             within 7 days prior to check-in.&#xD;
&#xD;
         24. Receipt of blood products within 2 months prior to check-in.&#xD;
&#xD;
         25. Donation of blood from 3 months prior to screening, plasma from 2 weeks prior to&#xD;
             screening, or platelets from 6 weeks prior to screening.&#xD;
&#xD;
         26. Poor peripheral venous access.&#xD;
&#xD;
         27. Subjects who, in the opinion of the investigator (or designee), should not participate&#xD;
             in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzhou Connect</last_name>
    <role>Study Director</role>
    <affiliation>Suzhou Connect Biopharmaceuticals, Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessie Chen</last_name>
    <phone>+8613913796870</phone>
    <email>jchen@connectpharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun Zhou</last_name>
    <phone>+8615358837581</phone>
    <email>jzhou@connectpharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CMAX</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

